MSMark Alexander Skarsfeldt

Mark Alexander Skarsfeldt

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mark Alexander Skarsfeldt has a total of 85 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Advances in Extracellular Matrix-Associated Diagnostics and Therapeutics

    by Morten Karsdal, Thomas R. Cox, Amelia L. Parker, Nicholas Willumsen, Jannie Marie Bülow Sand, Gisli Jenkins, Henrik H. Hansen, Anouk Oldenburger, Kerstin E. Geillinger-Kaestle, Anna Thorsø Larsen, et al.

    The extracellular matrix (ECM) is the common denominator of more than 50 chronic diseases. Some of these chronic pathologies lead to enhanced tissue formation and deposition, whereas others are associated with increased tissue degradation, and some exhibit a combination of both, leading to severe tissue alterations. To develop effective therapies for diseases affecting the lung, liver, kidney, skin, intestine, musculoskeletal system, heart, and solid tumors, we need to modulate the ECM’s composition to restore its organization and function. Across diverse organ diseases, there are common denominators and distinguishing factors in this fibroinflammatory axis, which may be used to foster new insights into drug development across disease indications. The 2nd Extracellular Matrix Pharmacology Congress took place in Copenhagen, Denmark, from 17 to 19 June 2024 and was hosted by the International Society of Extracellular Matrix Pharmacology. The event was attended by 450 participants from 35 countries, among whom were prominent scientists who brought together state-of-the-art research on organ diseases and asked important questions to facilitate drug development. We highlight key aspects of the ECM in the liver, kidney, skin, intestine, musculoskeletal system, lungs, and solid tumors to advance our understanding of the ECM and its central targets in drug development. We also highlight key advances in the tools and technology that enable this drug development, thereby supporting the ECM.


  • Treprostinil reduces clinically relevant fibrosis biomarkers in a Scar-in-a-Jar model using a fibrotic cocktail

    by Mark Skarsfeldt, Filipa B. Simões, Stine V. Johansen, Jannie M.B. Sand

    Aim: Fibroblast activation and collagen deposition is pivotal in development of fibrotic interstitial lung disease (ILD). Therefore, inhibiting these processes is crucial for anti-fibrotic therapies. This study aims to improve the Scar-in-a-Jar model by introducing a fibrotic cocktail (FC) of nine cytokines to better mimic the fibrogenic microenvironment. We examined how the FC affects collagen synthesis and explored Treprostinil's potential as an anti-fibrotic agent. Treprostinil, approved by the FDA for pulmonary arterial hypertension (PAH) and pulmonary hypertension in ILD (PH-ILD), is currently in phase 3 trials for the treatment of idiopathic pulmonary fibrosis, underlining its therapeutic prospect. Methods: Primary lung fibroblasts were exposed to the FC and Treprostinil (10-3000 nM) or vehicle for 12 days. Supernatants were collected every fourth day for quantification of type III and VI collagen synthesis (PRO-C3, PRO-C6) using the clinically relevant biomarker immunoassays NordicPRO-3TM and NordicPRO-C6TM. Results: Stimulating fibroblasts with the FC significantly increased PRO-3 and PRO-C6 levels (11.0 and 2.8-fold, p<0.0001) compared to non-stimulated cells at day 12. Treprostinil (10-3000 nM) significantly reduced PRO-C3 and PRO-C6 (2.95-8.4-fold and 1.7-3.3-fold, p<0.0001) in a concentration dependent manner compared to vehicle at day 12. Conclusions: The FC stimulates type III and type VI collagen synthesis in the Scar-in-a-Jar model which could be inhibited by Treprostinil. This model gives insight into collagen synthesis and therapeutic efficacy using clinically relevant biomarkers, contributing to development of novel anti-fibrotic therapies.

  • Polyunsaturated fatty acid‐derived IKs channel activators shorten the QT interval ex‐vivo and in‐vivo

    by Mark Alexander Skarsfeldt, Sara I. Liin, Hans P. Larsson, Bo Hjorth Bentzen

    Aim: We aimed to assess the ability of natural and modified polyunsaturated fatty acids (PUFAs) to shorten QT interval in ex‐vivo and in‐vivo guinea pig hearts.Methods: The effect of one natural (docosahexaenoic acid [DHA]) and three modified (linoleoyl glycine [Lin‐GLY], docosahexaenoyl glycine [DHA‐GLY], N‐arachidonoyl taurine [N‐AT]) PUFAs on ventricular action potential duration (APD) and QT interval was studied in a E4031 drug‐induced long QT2 model of ex‐vivo guinea pig hearts. The effect of DHA‐GLY on QT interval was also studied in in‐vivo guinea pig hearts upon intravenous administration. The effect of modified PUFAs on IKs was studied using Xenopus laevis oocytes expressing human KCNQ1 and KCNE1.Results: All tested PUFAs shortened ADP and QT interval in ex‐vivo guinea pig hearts, however, with different ability in restoring baseline APD/QT interval with specific modified PUFAs being most efficacious. Despite comparable ability in activating the human KCNQ1/KCNE1 channel, Lin‐GLY was not as effective in shortening APD/QT interval as DHA‐GLY in ex‐vivo hearts. By constructing a guinea pig‐like KCNE1, we found Lin‐GLY to induce less activating effect compared with DHA‐GLY on human KCNQ1 co‐expressed with guinea pig‐like KCNE1. Docosahexaenoyl glycine was studied in more detail and was found to shorten QT interval in in‐vivo guinea pig hearts.Conclusion: Our results show that specific PUFAs shorten QT interval in guinea pig hearts. The tendency of modified PUFAs with pronounced IKs channel activating effect to better restore QT interval suggests that modifying PUFAs to target the IKs channel is a means to improve the QT‐shortening effect.


  • Open Access

    Magnetocardiography on an isolated animal heart with a room-temperature optically pumped magnetometer

    by Kasper Jensen, Mark Alexander Skarsfeldt, Hans Stærkind, Jens Arnbak, Mikhail V. Balabas, Søren-Peter Olesen, Bo Hjorth Bentzen, Eugene S. Polzik

    Optically pumped magnetometers are becoming a promising alternative to cryogenically-cooled superconducting magnetometers for detecting and imaging biomagnetic fields. Magnetic field detection is a completely non-invasive method, which allows one to study the function of excitable human organs with a sensor placed outside the human body. For instance, magnetometers can be used to detect brain activity or to study the activity of the heart. We have developed a highly sensitive miniature optically pumped magnetometer based on cesium atomic vapor kept in a paraffin-coated glass container. The magnetometer is optimized for detection of biological signals and has high temporal and spatial resolution. It is operated at room- or human body temperature and can be placed in contact with or at a mm-distance from a biological object. With this magnetometer, we detected the heartbeat of an isolated guinea-pig heart, which is an animal widely used in biomedical studies. In our recordings of the magnetocardiogram, we can detect the P-wave, QRS-complex and T-wave associated with the cardiac cycle in real time. We also demonstrate that our device is capable of measuring the cardiac electrographic intervals, such as the RR- and QT-interval, and detecting drug-induced prolongation of the QT-interval, which is important for medical diagnostics.


  • Atrium‐specific ion channels in the zebrafish—A role of IKACh in atrial repolarization

    by M. A. Skarsfeldt, S. H. Bomholtz, P. R. Lundegaard, A. Lopez‐Izquierdo, M. Tristani‐Firouzi, B. H. Bentzen

    Aim: The zebrafish has emerged as a novel model for investigating cardiac physiology and pathology. The aim of this study was to investigate the atrium‐specific ion channels responsible for shaping the atrial cardiac action potential in zebrafish.Methods: Using quantitative polymerase chain reaction, we assessed the expression level of atrium‐specific potassium channels. The functional role of these channels was studied by patch clamp experiments on isolated atrial and ventricular cardiomyocytes and by optical mapping of explanted adult zebrafish hearts. Finally, surface ECGs were recorded to establish possible in vivo roles of atrial ion channels.Results: In isolated adult zebrafish hearts, we identified the expression of kcnk3, kcnk9, kcnn1, kcnn2, kcnn3, kcnj3 and kcnj5, the genes that encode the atrium‐specific K2P, KCa2.x and Kir3.1/4 (KACh) ion channels. The electrophysiological data indicate that the acetylcholine‐activated inward‐rectifying current, IKACh, plays a major role in the zebrafish atrium, whereas K2P3.1/9.1 and KCa2.x channels do not appear to be involved in regulating the action potential in the zebrafish heart.Conclusion: We demonstrate that the acetylcholine‐activated inward‐rectifying current (IKACh) current plays a major role in the zebrafish atrium and that the zebrafish could potentially be a cost‐effective and reliable model for pharmacological testing of atrium‐specific IKACh modulating compounds.


  • Open Access

    Electrophysiologic effects of theIK1inhibitor PA-6 are modulated by extracellular potassium in isolated guinea pig hearts

    by Gregory S. Hoeker, Mark A. Skarsfeldt, Thomas Jespersen, Steven Poelzing

    The pentamidine analog PA‐6 was developed as a specific inward rectifier potassium current ( I K1) antagonist, because established inhibitors either lack specificity or have side effects that prohibit their use in vivo. We previously demonstrated that BaCl2, an established I K1 inhibitor, could prolong action potential duration (APD) and increase cardiac conduction velocity (CV). However, few studies have addressed whether targeted I K1 inhibition similarly affects ventricular electrophysiology. The aim of this study was to determine the effects of PA‐6 on cardiac repolarization and conduction in Langendorff‐perfused guinea pig hearts. PA‐6 (200 nm) or vehicle was perfused into ex‐vivo guinea pig hearts for 60 min. Hearts were optically mapped with di‐4‐ANEPPS to quantify CV and APD at 90% repolarization (APD90). Ventricular APD90 was significantly prolonged in hearts treated with PA‐6 (115 ± 2% of baseline; P < 0.05), but not vehicle (105 ± 2% of baseline). PA‐6 slightly, but significantly, increased transverse CV by 7%. PA‐6 significantly prolonged APD90 during hypokalemia (2 mmol/L [K+]o), although to a lesser degree than observed at 4.56 mmol/L [K+]o. In contrast, the effect of PA‐6 on CV was more pronounced during hypokalemia, where transverse CV with PA‐6 (24 ± 2 cm/sec) was significantly faster than with vehicle (13 ± 3 cm/sec, P < 0.05). These results show that under normokalemic conditions, PA‐6 significantly prolonged APD90, whereas its effect on CV was modest. During hypokalemia, PA‐6 prolonged APD90 to a lesser degree, but profoundly increased CV. Thus, in intact guinea pig hearts, the electrophysiologic effects of the I K1 inhibitor, PA‐6, are [K+]o‐dependent.


  • Open Access

    Pharmacological inhibition ofIK1by PA-6 in isolated rat hearts affects ventricular repolarization and refractoriness

    by Mark A. Skarsfeldt, Helena Carstensen, Lasse Skibsbye, Chuyi Tang, Rikke Buhl, Bo H. Bentzen, Thomas Jespersen

    The inwardly rectifying potassium current (IK1) conducted through Kir2.X channels contribute to repolarization of the cardiac action potential and to stabilization of the resting membrane potential in cardiomyocytes. Our aim was to investigate the effect of the recently discovered IK1 inhibitor PA‐6 on action potential repolarization and refractoriness in isolated rat hearts. Transiently transfected HEK‐293 cells expressing IK1 were voltage‐clamped with ramp protocols. Langendorff‐perfused heart experiments were performed on male Sprague–Dawley rats, effective refractory period, Wenckebach cycle length, and ventricular effective refractory period were determined following 200 nmol/L PA‐6 perfusion. 200 nmol/L PA‐6 resulted in a significant time‐latency in drug effect on the IK1 current expressed in HEK‐293 cells, giving rise to a maximal effect at 20 min. In the Langendorff‐perfused heart experiments, PA‐6 prolonged the ventricular action potential duration at 90% repolarization (from 41.8 ± 6.5 msec to 72.6 ± 21.1 msec, 74% compared to baseline, P < 0.01, n = 6). In parallel, PA‐6 significantly prolonged the ventricular effective refractory period compared to baseline (from 34.8 ± 4.6 msec to 58.1 ± 14.7 msec, 67%, P < 0.01, n = 6). PA‐6 increased the short‐term beat‐to‐beat variability and ventricular fibrillation was observed in two of six hearts. Neither atrial ERP nor duration of atrial fibrillation was altered following PA‐6 application. The results show that pharmacological inhibition of cardiac IK1 affects ventricular action potential repolarization and refractoriness and increases the risk of ventricular arrhythmia in isolated rat hearts.


  • pH-dependent inhibition of K2P3.1 prolongs atrial refractoriness in whole hearts

    by Mark A. Skarsfeldt, Thomas A. Jepps, Sofia H. Bomholtz, Lea Abildgaard, Ulrik S. Sørensen, Emilie Gregers, Jesper H. Svendsen, Jonas G. Diness, Morten Grunnet, Nicole Schmitt, et al.

    In isolated human atrial cardiomyocytes, inhibition of K2P3.1 K+ channels results in action potential (action potential duration (APD)) prolongation. It has therefore been postulated that K2P3.1 (KCNK3), together with K2P9.1 (KCNK9), could represent novel drug targets for the treatment of atrial fibrillation (AF). However, it is unknown whether these findings in isolated cells translate to the whole heart. The purposes of this study were to investigate the expression levels of KCNK3 and KCNK9 in human hearts and two relevant rodent models and determine the antiarrhythmic potential of K2P3.1 inhibition in isolated whole-heart preparations. By quantitative PCR, we found that KCNK3 is predominantly expressed in human atria whereas KCNK9 was not detectable in heart human tissue. No differences were found between patients in AF or sinus rhythm. The expression in guinea pig heart resembled humans whereas rats displayed a more uniform expression of KCNK3 between atria and ventricle. In voltage-clamp experiments, ML365 and A293 were found to be potent and selective inhibitors of K2P3.1, but at pH 7.4, they failed to prolong atrial APD and refractory period (effective refractory period (ERP)) in isolated perfused rat and guinea pig hearts. At pH 7.8, which augments K2P3.1 currents, pharmacological channel inhibition produced a significant prolongation of atrial ERP (11.6 %, p = 0.004) without prolonging ventricular APD but did not display a significant antiarrhythmic effect in our guinea pig AF model (3/8 hearts converted on A293 vs 0/7 hearts in time-matched controls). These results suggest that when K2P3.1 current is augmented, K2P3.1 inhibition leads to atrial-specific prolongation of ERP; however, this ERP prolongation did not translate into significant antiarrhythmic effects in our AF model.


  • Polyunsaturated fatty acid analogs act antiarrhythmically on the cardiac I Ks channel

    by Sara I. Liin, Malin Silverå Ejneby, Rene Barro-Soria, Mark Alexander Skarsfeldt, Johan E. Larsson, Frida Starck Härlin, Teija Parkkari, Bo Hjorth Bentzen, Nicole Schmitt, H. Peter Larsson, et al.

    Significance: More than 300 mutations in the genes encoding the cardiac I Ks channel have been identified in patients with cardiac arrhythmia. These mutations cause either loss of function or gain of function of the I Ks channel. This study describes how polyunsaturated fatty acids and their analogues activate or inhibit the I Ks channel. These modulators can restore rhythmic firing in arrhythmic firing cardiac myocytes and restore prolonged QT interval in guinea pig hearts. The study also describes a mechanism by which an auxiliary β-subunit alters the pharmacological sensitivity of the I Ks channel. Our findings may form the basis for future design of antiarrhythmic compounds that target I Ks channels for treating different cardiac arrhythmias caused by mutations in the I Ks channel.